Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 40OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 7227Neoplasms 4535Prostatic Neoplasms 3486Colorectal Neoplasms 2930Carcinoma, Non-Small-Cell Lung 2823Lung Neoplasms 2539Leukemia, Myeloid, Acute 1980Pancreatic Neoplasms 1870Multiple Myeloma 1805Carcinoma, Hepatocellular 1729Neoplasm Metastasis 1585Stomach Neoplasms 1498Lymphoma 1455Precursor Cell Lymphoblastic Leukemia-Lymphoma 1434Head and Neck Neoplasms 1430Brain Neoplasms 1367Melanoma 1344Ovarian Neoplasms 1339Leukemia 1301Rectal Neoplasms 1266Recurrence 1249Colonic Neoplasms 1204Glioblastoma 1133Uterine Cervical Neoplasms 1090Lymphoma, Non-Hodgkin 1064Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 963Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 931Squamous Cell Carcinoma of Head and Neck 920

Interventions

Everolimus 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × Advanced Malignancies × Clear all
NCT06717880 2025-02-12

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Recruiting
260 enrolled

Advanced Malignancies

NCT01079702 2010-03-03

m-TOR

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Unknown
35 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡